Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

An insight into one of NICE’s most long-standing collaborative relationships. For nearly 20 years, NICE has worked with the ...

The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

In this episode, we hear from Professor Jonathan Benger, NICE's deputy chief executive and interim director of our Centre for Guidelines. He's joined by Dr Bryony Kendall who is a GP and sits on NICE ...

The evaluation committee considered evidence submitted by Santen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...